Prevalence of dyslipidemia and the relationship between HbA1C and lipid profile in Moroccan patients with T2DM: a cross-sectional study

Abstract

Introduction the increased prevalence of dyslipidemia in patients with type 2 diabetes mellitus (T2DM) results from uncontrolled hyperglycemia and consistently contributes to an elevated risk of cardiovascular complications. This study sought to estimate the prevalence of dyslipidemia and to investigate the relationship between glycated hemoglobin (HbA1C) and serum lipid levels in Moroccan patients with T2DM. Methods a total of 505 patients with T2DM were included in this cross-sectional study, 77.4% with chronic complications and 22.6% without. The collected data were examined using statistical package for the social sciences (SPSS) version 20.0 software and appropriate statistical methods. Results the data analysis showed that the mean and SD of age were 57.27±10.74 years. Among 505 patients with T2DM, the prevalence of hypercholesterolemia, hypertriglyceridemia, increased low-density lipoprotein cholesterol (LDL-C), and decreased HDL-C was 41.4%, 35.9%, 27.1%, and 17%, respectively. In addition, the data analysis showed that levels of total cholesterol (TC) (p≤0.001), triglycerides (p≤0.001), Low-density lipoprotein cholesterol (LDL-C) (p≤0.001), TC/HDL-C ratio (p=0.006), and LDL-C/HDL-C ratio (p=0.006) were significantly higher in T2DM patients with complications as compared to those without complications. The patients with HbA1C > 7.0% had significantly higher values of fasting blood glucose (FBG) (p≤0.001), total cholesterol (p≤0.001), triglycerides (p≤0.001), and TC/HDL-C ratio (p=0.025) as compared to the patients with HbA1C ≤ 7.0%. The HbA1C demonstrated a significant negative correlation with age (r=-0.139), and positive correlation with FBG (r=0.673), total cholesterol (r=0.189) and triglycerides (r=0.243). Conclusion our results showed that HbA1C is the most important biomarker of long-term glycemic control and can also be a good indicator of the lipid profile.

Macronutrient Intake and Association with the Risk Factors of Diabetic Complications among People with Type 2 Diabetes Mellitus in Al-Madinah Al-Munawara

“…The low prevalence rate, however, observed in this study for kidney diseases (5.4%) did not match the results obtained from other Arabic countries where the prevalence of kidney diseases in T2DM patients was 9.8% in Morocco [25], 25.2% in Libya [29], and 33.2% in Egypt [30]. The observed differences in the prevalence of kidney disease in the current and other studies could be attributed to the nature of our e-mailed sample, whereas other studies might include hospitalized patients who receive more advanced cases addressed to the nephrology department.…”

“…The prevalence of these complications showed no statistically significant differences in the studied male and female patients except for stroke, whose prevalence was higher among males (29.5% vs. 11.4%). These reported rates appeared high compared with a recent study conducted on 505 Moroccan patients with T2DM, where retinopathy disease was the most frequent diabetic complication (29.5%), followed by CVD (22.4%), diabetic kidney disease (9.8%), diabetes foot (2.8%), and neuropathy (1.8%) [25]. Most patients in that study, however, were women (85%), and in our study, the rate of complications was lower in the female patients studied, although not significant.…”

Prevalence of dyslipidemia among persons with type 2 diabetes in Africa: a systematic review and meta-analysis

“…Nigeria was the most prominently represented, with 14 articles 22 – 35 . This was followed by Ghana ( n =13) 36 – 48 , Ethiopia ( n =12) 49 – 60 , South Africa ( n =5) 61 – 65 , Kenya ( n =3) 66 – 68 , Sudan ( n =3) 69 – 71 , Eritrea ( n =2) 72 , 73 , and one article each from Algeria 74 , Egypt 75 , Morocco 76 , Somalia 77 , Tanzania 78 , Uganda 79 , and Zambia 80 . In total, 20 034 participants were studied, with sample sizes ranging from 100 to 2352.…”

Bioequivalence Study of Miglitol Orally Disintegrating Tablets in Healthy Chinese Volunteers Under Fasting Condition Based on Pharmacodynamic and Pharmacokinetic Parameters

“…Type 2 diabetes (T2D), accounting for more than 90% of diabetes cases worldwide, is characterized by insulin (ISL) resistance caused by ISL receptor insensitivity, chronic hyperglycemia, low‐grade inflammation, and dyslipidemia 1,3 . T2D has been reported to affect people's daily life and even cause some serious complications 1,2,4 . Presently, α‐glucosidase inhibitors (α‐GIs) have been proven to be the most effective treatment for controlling postprandial hyperglycemia and its detrimental physiological complications in T2D 5,6 …”

“…1,3 T2D has been reported to affect people's daily life and even cause some serious complications. 1,2,4 Presently, α-glucosidase inhibitors (α-GIs) have been proven to be the most effective treatment for controlling postprandial hyperglycemia and its detrimental physiological complications in T2D. 5,6 As an oral antihyperglycemic drug, α-GI delays the absorption of glucose by reversibly inhibiting α-glucosidase in the intestinal mucosa, thereby decreasing postprandial plasma glucose.…”